| Literature DB >> 29949587 |
Ming Zhong1, Biao Tang1, Qiang Zhao1, Jian Cheng1, Qiangsong Jin1, Shenwen Fu1.
Abstract
The KBI (kissing balloon inflation) technique is considered the default strategy for the two-stent approach in real world practice. Studies comparing KBI and No-KBI in patients undergoing the one-stent approach have reported conflicting results. The meta-analysis was performed to compare the clinical outcomes of the KBI strategy and the No-KBI strategy for coronary bifurcation lesions in the one-stent approach. Five randomized studies were included, and a total of 1264 patients were involved in the meta-analysis. The primary outcome was cardiac death. The secondary end points were stent thrombosis, MI (myocardial infarction), target lesion revascularization (TLR), target vessel revascularization (TVR), and main vessel and side branch restenosis. Compared with the No-KBI strategy, the KBI strategy was associated with a significant reduction in side branch restenosis (OR: 0.44, 95% CI: 0.30-0.64, p<0.001). A high risk of main vessel restenosis was found in the KBI group (OR: 2.96, 95% CI: 1.74-5.01, p<0.001). There were no significant differences in rates of cardiac death (OR: 1.89, 95% CI: 0.60-5.95, p = 0.28), stent thrombosis (OR: 0.98, 95% CI: 0.19-4.94, p = 0.98), MI (OR: 0.68, 95% CI: 0.33-1.44, p = 0.30), TLR (OR 1.14, 95% CI 0.68-1.90, p = 0.62), or TVR (OR 1.27, 95% CI 0.75-2.16, p = 0.38). Compared with the No-KBI strategy, the KBI strategy reduced the incidence of side branch restenosis and increased the risk of main branch restenosis in the one-stent approach. However, the clinical outcomes were similar between the KBI and No-KBI groups.Entities:
Mesh:
Year: 2018 PMID: 29949587 PMCID: PMC6021082 DOI: 10.1371/journal.pone.0197580
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics.
| Study | Year | Patients | Age | Man | DM | HP | LVEF | Jadad |
|---|---|---|---|---|---|---|---|---|
| Yamawaki et al. | 2017 | 113 | 69 | 90 | 41 | 82 | 64.3 ± 10.0; 63.7 ± 9.83 | 4 |
| Nordic III | 2011 | 477 | 65 | 347 | 81 | 303 | 58.0±11.0; 59.0±10.0 | 5 |
| CROSS | 2015 | 306 | 61 | 211 | 91 | 175 | 60.9±7.0; 62.2±5.7 | 4 |
| SMART-STRATEGY | 2012 | 258 | 62 | 213 | 70 | 145 | 59.3±10.7; 60.5±.3.0 | 4 |
| THUEBIS | 2009 | 110 | 66 | 82 | 28 | 91 | 62.4±9.9; 60.1±9.5 | 5 |
Values are the mean±SD; DM = diabetes mellitus; HP = hypertension; LVEF = left ventricular ejection fraction.
Procedural and follow-up characteristics.
| Study | KBI | NO-KBI | LM | Dual antiplatelet(months) | IVUS | MACE | Follow-Up(months) |
|---|---|---|---|---|---|---|---|
| Yamawaki et al. | 56 | 57 | No | NA | Yes | cardiac death, TLR, MI | 36 |
| Nordic III | 238 | 239 | Yes | 12 | No | cardiac death, MI, stent thrombosis, TLR | 6 |
| CROSS | 151 | 155 | No | 12 | Yes | comprising death, MI, TVR, TLR, MI | 12 |
| SMART-STRATEGY | 130 | 128 | Yes | NA | Yes | cardiac death, MI, TVR | 12 |
| THUEBIS | 56 | 54 | No | 6 | No | cardiac death, TLR, stent thrombosis. | 6 |
KBI = kissing balloon inflation; LM = left main; IVUS = intravascular ultrasound; MACE = major adverse cardiac events; TLR = target lesion revascularization; MI = myocardial infarction
TVR = target vessel revascularization; NA = not available.
Kind of stent for each study.
| Study | Yamawaki et al. | Nordic III | CROSS | SMART-STRATEGY | THUEBIS |
|---|---|---|---|---|---|
| KBI | Everolimus-eluting stents | Sirolimus-eluting cypher select+ | Sirolimus-eluting stents 47 (31.1); Paclitaxel-eluting stents 17 (11.3); Everolimus-eluting stents 33 (21.9); Zotarolimus-eluting stents 44 (29.1); Others 10 (6.6). | Sirolimus-eluting stent 60 (46.9); Everolimus-eluting stent 40 (31.3); | Taxus Express or Taxus Liberte stents |
| NO-KBI(%) | Sirolimus-eluting stents 36 (23.2); Paclitaxel-eluting stents 21 (13.5); Everolimus-eluting stents 36 (23.2); Zotarolimus-eluting stents 53 (34.2); Others 9 (5.8). | Sirolimus-eluting stent 62 (47.7); Everolimus-eluting stent 35 (26.9); |
KBI = kissing balloon inflation.